Literature DB >> 18809666

Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Gregory S Noland1, Brett Hendel-Paterson, Xinan M Min, Ann M Moormann, John M Vulule, David L Narum, David E Lanar, James W Kazura, Chandy C John.   

Abstract

In areas where levels of transmission of Plasmodium falciparum are high and stable, the age-related acquisition of high-level immunoglobulin G (IgG) antibodies to preerythrocytic circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) has been associated with protection from clinical malaria. In contrast, age-related protection from malaria develops slowly or not at all in residents of epidemic-prone areas with unstable low levels of malaria transmission. We hypothesized that this suboptimal clinical and parasitological immunity may in part be due to reduced antibodies to CSP or LSA-1 and/or vaccine candidate blood-stage antigens. Frequencies and levels of IgG antibodies to CSP, LSA-1, thrombospondin-related adhesive protein (TRAP), apical membrane antigen 1 (AMA-1), erythrocyte binding antigen 175 (EBA-175), and merozoite surface protein 1 (MSP-1) were compared in 243 Kenyans living in a highland area of unstable transmission and 210 residents of a nearby lowland area of stable transmission. Levels of antibodies to CSP, LSA-1, TRAP, and AMA-1 in the oldest age group (>40 years) in the unstable transmission area were lower than or similar to those of children 2 to 6 years old in the stable transmission area. Only 3.3% of individuals in the unstable transmission area had high levels of IgG (>2 arbitrary units) to both CSP and LSA-1, compared to 43.3% of individuals in the stable transmission area. In contrast, antibody levels to and frequencies of MSP-1 and EBA-175 were similar in adults in areas of stable and unstable malaria transmission. Suboptimal immunity to malaria in areas of unstable malaria transmission may relate in part to infrequent high-level antibodies to preerythrocytic antigens and AMA-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809666      PMCID: PMC2583556          DOI: 10.1128/IAI.00591-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum.

Authors:  D M Okenu; E M Riley; Q D Bickle; P U Agomo; A Barbosa; J R Daugherty; D E Lanar; D J Conway
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

3.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

4.  Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria.

Authors:  F Migot-Nabias; P Deloron; P Ringwald; B Dubois; J Mayombo; T N Minh; N Fievet; P Millet; A Luty
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

5.  Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

Authors:  Chandy C John; John H Ouma; Peter O Sumba; Michael R Hollingdale; James W Kazura; Chris L King
Journal:  Am J Trop Med Hyg       Date:  2002-04       Impact factor: 2.345

6.  Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.

Authors:  Kent E Kester; James F Cummings; Christian F Ockenhouse; Robin Nielsen; B Ted Hall; Daniel M Gordon; Robert J Schwenk; Urszula Krzych; Carolyn A Holland; Gregory Richmond; Megan G Dowler; Jackie Williams; Robert A Wirtz; Nadia Tornieporth; Laurence Vigneron; Martine Delchambre; Marie-Ange Demoitie; W Ripley Ballou; Joe Cohen; D Gray Heppner
Journal:  Vaccine       Date:  2008-03-13       Impact factor: 3.641

7.  Clinical epidemiology of malaria in the highlands of western Kenya.

Authors:  Simon I Hay; Abdisalan M Noor; Milka Simba; Millie Busolo; Helen L Guyatt; Sam A Ochola; Robert W Snow
Journal:  Emerg Infect Dis       Date:  2002-06       Impact factor: 6.883

8.  Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project.

Authors:  Z Zhou; L Xiao; O H Branch; S Kariuki; B L Nahlen; A A Lal
Journal:  Am J Trop Med Hyg       Date:  2002-01       Impact factor: 2.345

9.  Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Authors:  Issa Nebie; Amidou Diarra; Alphonse Ouedraogo; Issiaka Soulama; Edith C Bougouma; Alfred B Tiono; Amadou T Konate; Roma Chilengi; Michael Theisen; Daniel Dodoo; Ed Remarque; Samuel Bosomprah; Paul Milligan; Sodiomon B Sirima
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

10.  Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

Authors:  Christian Roussilhon; Claude Oeuvray; Christine Müller-Graf; Adama Tall; Christophe Rogier; Jean-François Trape; Michael Theisen; Aissatou Balde; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS Med       Date:  2007-11-13       Impact factor: 11.069

View more
  29 in total

Review 1.  Progress towards understanding the ecology and epidemiology of malaria in the western Kenya highlands: opportunities and challenges for control under climate change risk.

Authors:  A K Githeko; E N Ototo; Yan Guiyun
Journal:  Acta Trop       Date:  2011-10-12       Impact factor: 3.112

2.  A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Authors:  Stefan Kostense; Bregje Mommaas; Jenny Hendriks; Mariëlle Verhoeven; Mariska Ter Haak; Felicia Tirion; Edison Wiesken; Maria Grazia Pau; Katarina Radosevic; Jaap Goudsmit
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

3.  A Malaria-Resistant Phenotype with Immunological Correlates in a Tanzanian Birth Cohort Exposed to Intense Malaria Transmission.

Authors:  Scott D Nash; D Rebecca Prevots; Edward Kabyemela; Yogender P Khasa; Kun-Lin Lee; Michal Fried; Patrick E Duffy
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

4.  Development of clinical immunity to malaria in highland areas of low and unstable transmission.

Authors:  Melissa A Rolfes; Matthew McCarra; Ng'wena G Magak; Kacey C Ernst; Arlene E Dent; Kim A Lindblade; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2012-09-17       Impact factor: 2.345

5.  Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Authors:  Cysha E Hall; Lisa M Hagan; Elke Bergmann-Leitner; Donna M Tosh; Jason W Bennett; Jason A Regules; Ilin Chuang; Evelina Angov; Sheetij Dutta; Debasish Chattopadhyay; Anjali Yadava
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

6.  Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.

Authors:  Gregory S Noland; Paul Jansen; John M Vulule; Gregory S Park; Bartholomew N Ondigo; James W Kazura; Ann M Moormann; Chandy C John
Journal:  Acta Trop       Date:  2014-10-24       Impact factor: 3.112

7.  Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance.

Authors:  Fiona J McCallum; Kristina E M Persson; Freya J I Fowkes; Linda Reiling; Cleopatra K Mugyenyi; Jack S Richards; Julie A Simpson; Thomas N Williams; Paul R Gilson; Anthony N Hodder; Paul R Sanders; Robin F Anders; David L Narum; Chetan Chitnis; Brendan S Crabb; Kevin Marsh; James G Beeson
Journal:  J Leukoc Biol       Date:  2016-11-11       Impact factor: 4.962

8.  Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.

Authors:  Danica A Helb; Kevin K A Tetteh; Philip L Felgner; Jeff Skinner; Alan Hubbard; Emmanuel Arinaitwe; Harriet Mayanja-Kizza; Isaac Ssewanyana; Moses R Kamya; James G Beeson; Jordan Tappero; David L Smith; Peter D Crompton; Philip J Rosenthal; Grant Dorsey; Christopher J Drakeley; Bryan Greenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

9.  Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens.

Authors:  Bartholomew N Ondigo; James S Hodges; Kathleen F Ireland; Ng'wena G Magak; David E Lanar; Sheetij Dutta; David L Narum; Gregory S Park; Ayub V Ofulla; Chandy C John
Journal:  J Infect Dis       Date:  2014-04-15       Impact factor: 5.226

10.  Characteristic age distribution of Plasmodium vivax infections after malaria elimination on Aneityum Island, Vanuatu.

Authors:  Akira Kaneko; Luis F Chaves; George Taleo; Morris Kalkoa; Rie Isozumi; Renu Wickremasinghe; Hedvig Perlmann; Satoru Takeo; Takafumi Tsuboi; Shin-ichiro Tachibana; Masatsugu Kimura; Anders Björkman; Marita Troye-Blomberg; Kazuyuki Tanabe; Chris Drakeley
Journal:  Infect Immun       Date:  2013-10-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.